We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

77 hedge funds and large institutions have $616M invested in Arbutus Biopharma in 2015 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 17 increasing their positions, 8 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

841% more capital invested

Capital invested by funds: $65.5M → $616M (+$550M)

173% more call options, than puts

Call options by funds: $10.3M | Put options by funds: $3.78M

156% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 18

113% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 8

57% more funds holding

Funds holding: 49 → 77 (+28)

Holders
77
Holders Change
+28
Holders Change %
+57.14%
% of All Funds
2.05%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.05%
New
46
Increased
17
Reduced
8
Closed
18
Calls
$10.3M
Puts
$3.78M
Net Calls
+$6.52M
Net Calls Change
+$1.49M

Top Buyers

1
QF
QVT Financial
New York
+$328M
2
RCM
RA Capital Management
Massachusetts
+$55.6M
3
AWG
Alpha Wave Global
New York
+$45.5M
4
BRC
Blue Ridge Capital
New York
+$34.8M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$33.3M

Top Sellers

1
BBA
Baker Bros. Advisors
New York
-$6.22M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.95M
3
OSAM
O'Shaughnessy Asset Management
Connecticut
-$1.89M
4
NCCM
Nine Chapters Capital Management
New Jersey
-$1.11M
5
Deutsche Bank
Deutsche Bank
Germany
-$1.05M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACPU
26
Arrowgrass Capital Partners (US)
Delaware
$2.71M +$3.18M +155,000 New
B
27
Bailard
California
$2.43M +$1.21M +59,000 +74%
CM
28
Corvex Management
New York
$2.3M +$2.7M +131,900 New
DCM
29
Driehaus Capital Management
Illinois
$2.3M +$2.7M +131,736 New
SCM
30
Suffolk Capital Management
New York
$2.06M +$2.42M +118,100 New
Citigroup
31
Citigroup
New York
$1.54M -$26.1K -1,273 -1%
CS
32
Credit Suisse
Switzerland
$1.43M +$1.68M +81,819 New
SIA
33
Sit Investment Associates
Minnesota
$1.24M -$489K -23,850 -25%
Ameriprise
34
Ameriprise
Minnesota
$1.14M +$1.34M +65,240 New
MIG
35
Mariner Investment Group
New York
$1.14M +$1.33M +65,000 New
MIM
36
Monashee Investment Management
Massachusetts
$960K +$1.13M +55,000 New
WSA
37
Wall Street Associates
California
$931K +$1.09M +53,338 New
TI
38
Telemetry Investments
New York
$838K +$256K +12,500 +35%
Deutsche Bank
39
Deutsche Bank
Germany
$738K -$1.05M -51,416 -55%
Mackenzie Financial
40
Mackenzie Financial
Ontario, Canada
$697K +$817K +39,900 New
Canada Life
41
Canada Life
Manitoba, Canada
$695K +$479K +23,400 +142%
Morgan Stanley
42
Morgan Stanley
New York
$665K +$180K +8,801 +30%
Toronto Dominion Bank
43
Toronto Dominion Bank
Ontario, Canada
$646K +$757K +36,963 +99,900%
GC
44
Guggenheim Capital
Illinois
$628K +$737K +36,000 New
Barclays
45
Barclays
United Kingdom
$592K +$675K +32,939 +1,753%
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$575K +$77.9K +3,802 +13%
VAM
47
Visium Asset Management
New York
$524K +$615K +30,000 New
AFM
48
Anson Funds Management
Texas
$437K +$512K +25,000 New
EAM
49
EverPoint Asset Management
Connecticut
$437K +$512K +25,000 New
QSS
50
Quantitative Systematic Strategies
Florida
$382K +$442K +21,588 New
1
2
3 4

ABUS Hedge Fund Activity: Q1 2015 in Review

77 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q1 2015, worth a combined $616M — up 841% from $65.5M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new ABUS positions and 18 closed out — a net gain of 28 holders — while 17 added to existing stakes and 8 trimmed.

The largest buyer was QVT Financial, opening a new position worth an estimated $328M. The largest seller was Baker Bros. Advisors, cutting an estimated $6.22M.

  • 77 institutional investors held Arbutus Biopharma (ABUS) as of Q1 2015, up from 49 in Q4 2014.
  • Funds reported $616M of Arbutus Biopharma stock for Q1 2015, up 841% quarter-over-quarter.
  • 46 funds opened new Arbutus Biopharma positions in Q1 2015 and 18 closed out, a net change of +28 holders.
  • The largest Arbutus Biopharma buyer in Q1 2015 was QVT Financial, an estimated $328M added.
  • The largest Arbutus Biopharma seller in Q1 2015 was Baker Bros. Advisors, an estimated $6.22M sold.

Based on aggregated 13F filings for Q1 2015.